[Pomalidomide for multiple myeloma]

Aurore Dougé; Richard Lemal; Carine Chaleteix

doi:10.1016/j.bulcan.2017.04.005

[Pomalidomide for multiple myeloma]

Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.

[Article in French]

Authors

Aurore Dougé¹, Richard Lemal², Carine Chaleteix³

Affiliations

¹ CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France. Electronic address: adouge@chu-clermontferrand.fr.
² CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
³ CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France.

PMID: 28583668
DOI: 10.1016/j.bulcan.2017.04.005

Abstract

Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.

Keywords: IMID; Multiple myeloma; Myélome multiple; Pomalidomide; Rechute ou réfractaire; Relapsed or refractory.

MeSH terms

Clinical Trials as Topic
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Multiple Myeloma / drug therapy*
Thalidomide / analogs & derivatives*
Thalidomide / pharmacology
Thalidomide / therapeutic use

Substances

Immunologic Factors
Thalidomide
pomalidomide